Christine Berg | |
|---|---|
 Berg in 2004 | |
| Alma mater | Northwestern University School of Medicine |
| Scientific career | |
| Fields | Radiation oncology, cancer prevention |
| Institutions | National Cancer Institute |
Christine Dorothy Berg is an American radiation oncologist and physician-scientist who was chief of the early detection research group at the National Cancer Institute.
Berg completed a M.D. at the Northwestern University School of Medicine. [1] She completed a residency in internal medicine from 1977 to 1981 at the McGaw Medical Center. [1] Berg conducted a fellowship in hematology and medical oncology from 1981 to 1984 at the National Institutes of Health Clinical Center. [1] She was a resident in radiation oncology from 1984 to 1986 with MedStar Health. [1]
As of 2004, Berg was chief of the early detection research group in the division of cancer prevention at the National Cancer Institute. [2] In 2010, she was co-lead of the National Lung Screening Trial. [3] Berg retired from NCI in November 2012. [2]
M. Krishnan Nair was an Indian oncologist. He was the founding director of the Regional Cancer Centre, Thiruvananthapuram, a director of the S.U.T. Institute of Oncology, and Trivandrum Cancer Center(TCC), part of SUT Royal Hospital in Thiruvananthapuram (Trivandrum) and a professor at the Amrita Institute of Medical Sciences & Research in Kochi. The Government of India awarded him the fourth highest civilian award of the Padma Shri in 2001 for his contributions in the cancer care field.
Lung cancer screening refers to cancer screening strategies used to identify early lung cancers before they cause symptoms, at a point where they are more likely to be curable. Lung cancer screening is critically important because of the incidence and prevalence of lung cancer. More than 235,000 new cases of lung cancer are expected in the United States in 2021 with approximately 130,000 deaths expected in 2021. In addition, at the time of diagnosis, 57% of lung cancers are discovered in advanced stages, meaning they are more widespread or aggressive cancers. Because there is a substantially higher probability of long-term survival following treatment of localized (60%) versus advanced stage (6%) lung cancer, lung cancer screening aims to diagnose the disease in the localized stage.
The "war on cancer" is the effort to find a cure for cancer by increased research to improve the understanding of cancer biology and the development of more effective cancer treatments, such as targeted drug therapies. The aim of such efforts is to eradicate cancer as a major cause of death. The signing of the National Cancer Act of 1971 by United States president Richard Nixon is generally viewed as the beginning of this effort, though it was not described as a "war" in the legislation itself.
The objective of cancer screening is to detect cancer before symptoms appear, involving various methods such as blood tests, urine tests, DNA tests, and medical imaging. The purpose of screening is early cancer detection, to make the cancer easier to treat and extending life expectancy. In 2019, cancer was the second leading cause of death globally; more recent data is pending due to the COVID-19 pandemic.
Waun Ki Hong was Professor of Medicine at The University of Texas MD Anderson Cancer Center, where he served as chairman of the Department of Thoracic/Head & Neck Medical Oncology from 1993 to 2005 and as head of the Division of Cancer Medicine from 2001 to 2014. He was also an American Cancer Society Professor and the Samsung Distinguished University Chair in Cancer Medicine emeritus.
Amy Berrington de González is a scientist. She is a senior investigator and radiation epidemiology branch chief at the National Cancer Institute.
Deborah Watkins Bruner is an American researcher, clinical trialist, and academic. She is the senior vice president for research at Emory University. Her research focus is on patient reported outcomes, symptom management across cancer sites, sexuality after cancer treatment, and effectiveness of radiotherapy modalities. Bruner's research has been continually funding since 1998, with total funding of her research exceeding $180 million. She is ranked among the top five percent of all National Institutes of Health-funded investigators worldwide since 2012, according to the Blue Ridge Institute for Medical Research.
Christine Campo Alewine is an American oncologist and biologist researching immunotoxin therapeutics in pancreatic cancer. She is an investigator at the National Cancer Institute.
Jacqueline Jia-Kang Whang-Peng is a Taiwanese-American physician-scientist specialized in cytogenetics of cancer, as well as medical genetics, genetic oncology, and gene mapping. She was a researcher at the National Cancer Institute from 1960 to 1993.
Worta J. McCaskill-Stevens was an American physician-scientist and medical oncologist specialized in cancer disparities research, management of comorbidities within clinical trials, and molecular research for cancer prevention interventions. She was chief of the community oncology and prevention trials research group at the National Cancer Institute.
Elaine Straus Ron was an American epidemiologist specializing in radiation and thyroid cancer. She was a senior investigator in the radiation epidemiology branch at the National Cancer Institute. Ron was an advocate for women in science.
Ruth A. Kleinerman is an American epidemiologist specialized in retinoblastoma. Kleinerman worked at the National Cancer Institute (NCI) from 1979 to 2019 where she served as a staff scientist and deputy chief of the Radiation Epidemiology Branch.
Bríd M. Ryan is an Irish biomedical scientist and cancer researcher. She was an investigator at the National Cancer Institute from 2013 to 2021.
Sharon A. Savage is an American pediatric hematologist/oncologist. She is the clinical director of the National Cancer Institute's Division of Cancer Epidemiology and Genetics.
Jennifer T. Loud is an American nurse practitioner who served as the assistant chief of the National Cancer Institute's clinical genetics branch until August 2020.
Brigitte C. Widemann is German-American pediatric oncologist. She is chief of the pediatric oncology branch and clinical deputy director of the center for cancer research at the National Cancer Institute. She is also the special advisor to the NCI director for childhood cancer.
Amanda Black is a Northern Irish epidemiologist who is the associate director of biological resources in the National Cancer Institute's division of cancer epidemiology and genetics.
Margaret Anne Tucker is an American oncologist and physician-scientist specialized in environmental and genetic epidemiology, familial cancers, and melanomas. She is a scientist emeritia at the National Cancer Institute (NCI). Tucker was a commissioned officer in the United States Public Health Service Commissioned Corps and served as director of the NCI human genetics program from 2005 until her retirement in June 2018.
Mary Lou McMaster is an American oncologist and clinical trialist who researches familial cancer genetics. She is a senior clinical trial specialist at the National Cancer Institute and a captain in the United States Public Health Service Commissioned Corps.
Kathy J. Helzlsouer is an American oncologist, internist, and cancer epidemiologist who investigates cancer etiology and prevention, women's health, genetic counseling, and translational research. At the National Cancer Institute, she is the associate director of the epidemiology and genomics research program and chief medical officer for the division of cancer control and population sciences.
This article incorporates text from this source, which is in the public domain . This article incorporates public domain material from websites or documents of the National Institutes of Health.| International | |
|---|---|
| National | |
| Academics | |
